- $725.99m
- $674.90m
- $183.88m
Brief: Geron Q3 EPS USD -0.04 Vs. IBES Estimate USD -0.08
Geron Corp reports results for the quarter ended in June - Earnings Summary
Brief: Geron Q2 EPS USD -0.1 Vs. IBES Estimate USD -0.1
Geron Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Geron Updates NCCN Guidelines Recommending RYTELO for Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
Geron falls as chief commercial officer set to leave
U.S. RESEARCH ROUNDUP-ACV Auctions, Asbury Automotive Group, Walmart
U.S. RESEARCH ROUNDUP-Acv Auctions, Asbury Automotive Group, Walmart
U.S. STOCKS ON THE MOVE-Vail Resorts, Celanese, Graham
Geron gains after winning first FDA approval for blood disorder drug
U.S. STOCKS ON THE MOVE-Semtech, United Rentals, Toro
U.S. STOCKS ON THE MOVE-Lyft, Geron, Gamestop
Geron shares surge after U.S. FDA approves blood disorder drug (updated)
Geron shares surge after U.S. FDA approves blood disorder drug
Geron gains as FDA approves blood disorder drug
Brief: Geron Announces FDA Approval Of Rytelo For Treatment Of Adult Patients With Lower-Risk Mds With Transfusion-Dependent Anemia
Geron Corp reports results for the quarter ended in March - Earnings Summary